Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.37 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20633689 | 0.98 | OR51E2 (0.37) | OR51E2CRBNFKBP5GAASMN1; SMN2 | |
| SCHEMBL9986841 | 0.94 | OR51E2 (0.34) | OR51E2CRBNFKBP5GAAOPRM1 | |
| SCHEMBL16190024 | 0.90 | — | — | |
| SCHEMBL1133336 | 0.86 | NEK2 (0.39) | OR51E2CRBNFKBP5GAASMN1; SMN2 | |
| SCHEMBL18132114 | 0.81 | ALDH1A1 (0.37) | OR51E2CRBNFKBP5SMN1; SMN2OPRM1 | |
| SCHEMBL31580458 | 0.81 | OPRM1 (0.42) | OR51E2CRBNFKBP5GAASMN1; SMN2 | |
| SCHEMBL23119745 | 0.80 | GAA (0.48) | OR51E2GAA | |
| SCHEMBL9986299 | 0.80 | GAA (0.36) | GAA | |
| SCHEMBL20758273 | 0.79 | SMN1; SMN2 (0.35) | OR51E2CRBNFKBP5GAASMN1; SMN2 | |
| SCHEMBL2522078 | 0.78 | OPRM1 (0.47) | CRBNSMN1; SMN2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032560-B1 | POSITION-4 SUBSTITUTED 2-PYRROLIDINONE DERIVATIVES TO REDUCE THE LEVEL OF EXTRACELLULAR GLUTAMATE | UNIV LUDWIGS ALBERT (DE) | 2004-12-29 | — | — | EP | claimed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | OR51E2 3027/4885CRBN 630/4885FKBP5 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.